Literature DB >> 2865943

Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.

.   

Abstract

Six hundred sixteen eyes with recent severe diabetic vitreous hemorrhage reducing visual acuity to 5/200 or less for at least one month were randomly assigned to either early vitrectomy or deferral of vitrectomy for one year. After two years of follow-up, 25% of the early vitrectomy group had visual acuity of 10/20 or better compared with 15% in the deferral group (P = .01). In patients with Type I diabetes, who were on the average younger and had more-severe proliferative retinopathy, there was a clear-cut advantage for early vitrectomy, as reflected in the percentage of eyes recovering visual acuity of 10/20 or better (36% vs 12% in the deferral group, P = .0001). No such advantage was found in the Type II diabetes group (16% in the early group vs 18% in the deferral group), but evidence that this advantage differed by diabetes type was of borderline significance.

Entities:  

Mesh:

Year:  1985        PMID: 2865943

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  60 in total

1.  Macular morphologic findings on optical coherence tomography after microincision vitrectomy for proliferative diabetic retinopathy.

Authors:  Tomoaki Murakami; Akihito Uji; Ken Ogino; Noriyuki Unoki; Shin Yoshitake; Yoko Dodo; Takahiro Horii; Kazuaki Nishijima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2015-05-09       Impact factor: 2.447

2.  Severe vitreous hemorrhage associated with closed-globe injury.

Authors:  Ling Yeung; Tun-Lu Chen; Ya-Hui Kuo; An-Ning Chao; Wei-Chi Wu; Kuan-Jen Chen; Yih-Shiou Hwang; Yen- Po Chen; Chi-Chun Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-26       Impact factor: 3.117

3.  Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.

Authors:  G Ratnarajan; F Mellington; M Saldanha; S R de Silva; L Benjamin
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

4.  INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY DURING VITREORETINAL SURGERY FOR DENSE VITREOUS HEMORRHAGE IN THE PIONEER STUDY.

Authors:  Justis P Ehlers; Joseph F Griffith; Sunil K Srivastava
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

5.  Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes.

Authors:  Chu-Hsuan Huang; Yi-Ting Hsieh; Chung-May Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-06       Impact factor: 3.117

6.  An optical coherence tomography study of residual subfoveal fluid after successful pars plana vitrectomy in patients with diabetic tractional macular detachment.

Authors:  Mushfig I Karimov; Elmar M Gasymov; Irada J Aliyeva; Lale A Akhundova; Gunay R Rustambayova; Khalid D Aliyev
Journal:  Eye (Lond)       Date:  2018-05-23       Impact factor: 3.775

7.  Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice.

Authors:  B Gupta; R Wong; S Sivaprasad; T H Williamson
Journal:  Eye (Lond)       Date:  2012-01-13       Impact factor: 3.775

Review 8.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

9.  The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards.

Authors:  Mary Gilbert Lawrence
Journal:  Trans Am Ophthalmol Soc       Date:  2004

10.  Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.

Authors:  Siamak Moradian; Hamid Ahmadieh; Mohsen Malihi; Masoud Soheilian; Mohammad Hossein Dehghan; Mohsen Azarmina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.